Izotropic Corporation (IZOZF)
- Newsfile
Izotropic Corporation Announces Closing of First Tranche of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - June 14, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company") - Further to the Company's news release of June 6, 2024, the Company is pleased to announce that it has completed the first tranche of its non-brokered private placement financing (the "Offering"), whereby the Company issued 1,800,000 units (each, a "Unit") at a price of $0.10 per Unit for gross proceeds of $180,000.00. ...
- Newsfile
Izotropic Corporation Announces Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - June 6, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing IzoView, a CT (computed tomography) imaging system, announced today that it intends to complete a small non-brokered private placement financing (the "Offering") of up to 3,000,000 units of the Company, (each a "Unit") at a price of $0.10 per each Unit for a gross proceeds of up to $300,000.00. ...
- Newsfile
Izotropic Receives Response From U.S. FDA
Vancouver, British Columbia--(Newsfile Corp. - January 30, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing IzoView, a CT (computed tomography) imaging system, that produces images of anatomy for non-invasive characterization of tissue with an application in breast imaging, announces that further to its January 8th disclosure, it has received a response from the U.S. FDA. The FDA's mammogram and ultrasound
